drugset
drugset / Trial / NCT04682106

A Study of LY3493269 in Healthy Participants

NCT04682106 ↗

Phase 1 Completed 40 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3493269 in healthy participants. The blood tests will be performed to check how much LY3493269 gets into the bloodstream, how long the body takes to eliminate it and how body handles LY3493269. The study will last up to approximately 71 days for each participant, including screening

Timeline

Start
2021-05-03
Primary completion
2021-11-11
Completion
2021-11-11

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3493269 Unknown 4 mg Oral
Subject LY3493269 Unknown 8 mg Oral
Subject LY3493269 Unknown 12 mg Oral
Subject LY3493269 Unknown 24 mg Oral
Background Salcaprozate Sodium Unknown 300 mg Oral
Background Salcaprozate Sodium Unknown 600 mg Oral

Indications

No indication recorded.